FEB 19, 2015
Comprehensive Ophthalmology, Retina/Vitreous
The National Institute for Health and Care Excellence today issued draft guidance recommending approval of the dexamethasone (Ozurdex, Allergan) implant for diabetic macular edema (DME).
The preliminary guidelines suggest the implant be an option only in pseudophakic patients insufficiently responsive to or unsuitable for noncorticosteroid therapy.
The dexamethasone implant is injected into the eye once every six months and works by suppressing inflammation and preventing edema forming in the eye.